ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 59 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,851,000 | -74.7% | 250,484 | -50.2% | 0.08% | -64.9% |
| Q3 2018 | $7,304,000 | -37.5% | 502,996 | -14.0% | 0.22% | -43.0% |
| Q2 2018 | $11,687,000 | +12.8% | 585,208 | -1.0% | 0.40% | +7.9% |
| Q1 2018 | $10,357,000 | -19.8% | 591,176 | +12.9% | 0.37% | -25.3% |
| Q4 2017 | $12,908,000 | +66.1% | 523,428 | +73.8% | 0.49% | +61.7% |
| Q3 2017 | $7,773,000 | +4.0% | 301,174 | +9.3% | 0.30% | +10.2% |
| Q2 2017 | $7,475,000 | -24.3% | 275,610 | -16.8% | 0.28% | -18.6% |
| Q1 2017 | $9,876,000 | -22.2% | 331,197 | -29.2% | 0.34% | -24.7% |
| Q4 2016 | $12,700,000 | +171.1% | 467,937 | +155.8% | 0.45% | +184.2% |
| Q3 2016 | $4,685,000 | – | 182,935 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
| Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
| GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
| Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
| VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
| Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
| Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
| BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |